{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,6]],"date-time":"2026-05-06T06:30:53Z","timestamp":1778049053561,"version":"3.51.4"},"reference-count":39,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2019,4,30]],"date-time":"2019-04-30T00:00:00Z","timestamp":1556582400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2019,4,30]],"date-time":"2019-04-30T00:00:00Z","timestamp":1556582400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Invest New Drugs"],"published-print":{"date-parts":[[2019,6,15]]},"DOI":"10.1007\/s10637-019-00778-4","type":"journal-article","created":{"date-parts":[[2019,4,30]],"date-time":"2019-04-30T13:12:19Z","timestamp":1556629939000},"page":"559-566","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":14,"title":["Randomized phase II trial of neoadjuvant everolimus in patients with high-risk localized prostate cancer"],"prefix":"10.1007","volume":"37","author":[{"given":"Vadim S.","family":"Koshkin","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Maria C.","family":"Mir","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Pedro","family":"Barata","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Anita","family":"Gul","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ruby","family":"Gupta","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Andrew J.","family":"Stephenson","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jihad","family":"Kaouk","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ryan","family":"Berglund","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Cristina","family":"Magi-Galluzzi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Eric A.","family":"Klein","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Robert","family":"Dreicer","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jorge A.","family":"Garcia","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2019,4,30]]},"reference":[{"issue":"11","key":"778_CR1","doi-asserted-by":"publisher","first-page":"969","DOI":"10.1001\/jama.280.11.969","volume":"280","author":"AV D'Amico","year":"1998","unstructured":"D'Amico AV, Whittington R, Malkowicz SB, Schultz D, Blank K, Broderick GA et al (1998) Biochemical outcome after radical prostatectomy, external beam radiation therapy, or interstitial radiation therapy for clinically localized prostate cancer. Jama. 280(11):969\u2013974","journal-title":"Jama."},{"issue":"1","key":"778_CR2","doi-asserted-by":"publisher","first-page":"117","DOI":"10.1016\/S0022-5347(05)65394-3","volume":"167","author":"WK Lau","year":"2002","unstructured":"Lau WK, Bergstralh EJ, Blute ML, Slezak JM, Zincke H (2002) Radical prostatectomy for pathological Gleason 8 or greater prostate cancer: influence of concomitant pathological variables. J Urol 167(1):117\u2013122","journal-title":"J Urol"},{"issue":"16","key":"778_CR3","doi-asserted-by":"publisher","first-page":"3376","DOI":"10.1200\/JCO.2002.01.150","volume":"20","author":"PA Kupelian","year":"2002","unstructured":"Kupelian PA, Elshaikh M, Reddy CA, Zippe C, Klein EA (2002) Comparison of the efficacy of local therapies for localized prostate cancer in the prostate-specific antigen era: a large single-institution experience with radical prostatectomy and external-beam radiotherapy. J Clin Oncol 20(16):3376\u20133385","journal-title":"J Clin Oncol"},{"issue":"6","key":"778_CR4","doi-asserted-by":"publisher","first-page":"561","DOI":"10.1046\/j.1464-410X.2002.02982.x","volume":"90","author":"G Aus","year":"2002","unstructured":"Aus G, Abrahamsson PA, Ahlgren G, Hugosson J, Lundberg S, Schain M, Schelin S, Pedersen K (2002) Three-month neoadjuvant hormonal therapy before radical prostatectomy: a 7-year follow-up of a randomized controlled trial. BJU Int 90(6):561\u2013566","journal-title":"BJU Int"},{"issue":"2 Pt 1","key":"778_CR5","first-page":"429","volume":"154","author":"H Van Poppel","year":"1995","unstructured":"Van Poppel H, De Ridder D, Elgamal AA, Van de Voorde W, Werbrouck P, Ackaert K et al (1995) Neoadjuvant hormonal therapy before radical prostatectomy decreases the number of positive surgical margins in stage T2 prostate cancer: interim results of a prospective randomized trial. The Belgian Uro-oncological study group. J Urol 154(2 Pt 1):429\u2013434","journal-title":"J Urol"},{"issue":"2","key":"778_CR6","doi-asserted-by":"publisher","first-page":"500","DOI":"10.1016\/S0022-5347(05)65971-X","volume":"166","author":"ME Gleave","year":"2001","unstructured":"Gleave ME, Goldenberg SL, Chin JL, Warner J, Saad F, Klotz LH et al (2001) Randomized comparative study of 3 versus 8-month neoadjuvant hormonal therapy before radical prostatectomy: biochemical and pathological effects. J Urol 166(2):500\u2013506 discussion 6-7","journal-title":"J Urol"},{"issue":"3","key":"778_CR7","doi-asserted-by":"publisher","first-page":"791","DOI":"10.1097\/01.ju.0000081404.98273.fd","volume":"170","author":"LH Klotz","year":"2003","unstructured":"Klotz LH, Goldenberg SL, Jewett MA, Fradet Y, Nam R, Barkin J et al (2003) Long-term followup of a randomized trial of 0 versus 3 months of neoadjuvant androgen ablation before radical prostatectomy. J Urol 170(3):791\u2013794","journal-title":"J Urol"},{"issue":"4 Suppl 15","key":"778_CR8","doi-asserted-by":"publisher","first-page":"40","DOI":"10.1016\/S0093-7754(01)90153-8","volume":"28","author":"WK Oh","year":"2001","unstructured":"Oh WK, George DJ, Kaufman DS, Moss K, Smith MR, Richie JP et al (2001) Neoadjuvant docetaxel followed by radical prostatectomy in patients with high-risk localized prostate cancer: a preliminary report. Semin Oncol 28(4 Suppl 15):40\u201344","journal-title":"Semin Oncol"},{"issue":"6","key":"778_CR9","doi-asserted-by":"publisher","first-page":"1138","DOI":"10.1016\/j.urology.2004.01.040","volume":"63","author":"R Dreicer","year":"2004","unstructured":"Dreicer R, Magi-Galluzzi C, Zhou M, Rothaermel J, Reuther A, Ulchaker J, Zippe C, Fergany A, Klein EA (2004) Phase II trial of neoadjuvant docetaxel before radical prostatectomy for locally advanced prostate cancer. Urology 63(6):1138\u20131142","journal-title":"Urology"},{"issue":"4","key":"778_CR10","doi-asserted-by":"publisher","first-page":"1306","DOI":"10.1158\/1078-0432.CCR-1021-03","volume":"10","author":"TM Beer","year":"2004","unstructured":"Beer TM, Garzotto M, Lowe BA, Ellis WJ, Montalto MA, Lange PH, Higano CS (2004) Phase I study of weekly mitoxantrone and docetaxel before prostatectomy in patients with high-risk localized prostate cancer. Clin Cancer Res 10(4):1306\u20131311","journal-title":"Clin Cancer Res"},{"issue":"14","key":"778_CR11","doi-asserted-by":"publisher","first-page":"5233","DOI":"10.1158\/1078-0432.CCR-05-0299","volume":"11","author":"PG Febbo","year":"2005","unstructured":"Febbo PG, Richie JP, George DJ, Loda M, Manola J, Shankar S et al (2005) Neoadjuvant docetaxel before radical prostatectomy in patients with high-risk localized prostate cancer. Clin Cancer Res 11(14):5233\u20135240","journal-title":"Clin Cancer Res"},{"issue":"6","key":"778_CR12","doi-asserted-by":"publisher","first-page":"1075","DOI":"10.1200\/JCO.2009.25.3641","volume":"28","author":"KD Courtney","year":"2010","unstructured":"Courtney KD, Corcoran RB, Engelman JA (2010) The PI3K pathway as drug target in human cancer. J Clin Oncol 28(6):1075\u20131083","journal-title":"J Clin Oncol"},{"issue":"11","key":"778_CR13","doi-asserted-by":"publisher","first-page":"2762","DOI":"10.1002\/jcp.22647","volume":"226","author":"JA McCubrey","year":"2011","unstructured":"McCubrey JA, Steelman LS, Kempf CR, Chappell WH, Abrams SL, Stivala F et al (2011) Therapeutic resistance resulting from mutations in Raf\/MEK\/ERK and PI3K\/PTEN\/Akt\/mTOR signaling pathways. J Cell Physiol 226(11):2762\u20132781","journal-title":"J Cell Physiol"},{"issue":"1","key":"778_CR14","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1016\/j.ccr.2010.05.026","volume":"18","author":"BS Taylor","year":"2010","unstructured":"Taylor BS, Schultz N, Hieronymus H, Gopalan A, Xiao Y, Carver BS, Arora VK, Kaushik P, Cerami E, Reva B, Antipin Y, Mitsiades N, Landers T, Dolgalev I, Major JE, Wilson M, Socci ND, Lash AE, Heguy A, Eastham JA, Scher HI, Reuter VE, Scardino PT, Sander C, Sawyers CL, Gerald WL (2010) Integrative genomic profiling of human prostate cancer. Cancer Cell 18(1):11\u201322","journal-title":"Cancer Cell"},{"issue":"15","key":"778_CR15","doi-asserted-by":"publisher","first-page":"5232","DOI":"10.1158\/0008-5472.CAN-04-0272","volume":"64","author":"JI Kreisberg","year":"2004","unstructured":"Kreisberg JI, Malik SN, Prihoda TJ, Bedolla RG, Troyer DA, Kreisberg S, Ghosh PM (2004) Phosphorylation of Akt (Ser473) is an excellent predictor of poor clinical outcome in prostate cancer. Cancer Res 64(15):5232\u20135236","journal-title":"Cancer Res"},{"issue":"19","key":"778_CR16","doi-asserted-by":"publisher","first-page":"6572","DOI":"10.1158\/1078-0432.CCR-04-0477","volume":"10","author":"G Ayala","year":"2004","unstructured":"Ayala G, Thompson T, Yang G, Frolov A, Li R, Scardino P et al (2004) High levels of phosphorylated form of Akt-1 in prostate cancer and non-neoplastic prostate tissues are strong predictors of biochemical recurrence. Clin Cancer Res 10(19):6572\u20136578","journal-title":"Clin Cancer Res"},{"issue":"13","key":"778_CR17","doi-asserted-by":"publisher","first-page":"3860","DOI":"10.1158\/1078-0432.CCR-07-0091","volume":"13","author":"R Bedolla","year":"2007","unstructured":"Bedolla R, Prihoda TJ, Kreisberg JI, Malik SN, Krishnegowda NK, Troyer DA, Ghosh PM (2007) Determining risk of biochemical recurrence in prostate cancer by immunohistochemical detection of PTEN expression and Akt activation. Clin Cancer Res 13(13):3860\u20133867","journal-title":"Clin Cancer Res"},{"issue":"21","key":"778_CR18","doi-asserted-by":"publisher","first-page":"4521","DOI":"10.1002\/pmic.200800113","volume":"8","author":"I Skvortsova","year":"2008","unstructured":"Skvortsova I, Skvortsov S, Stasyk T, Raju U, Popper BA, Schiestl B, von Guggenberg E, Neher A, Bonn GK, Huber LA, Lukas P (2008) Intracellular signaling pathways regulating radioresistance of human prostate carcinoma cells. Proteomics 8(21):4521\u20134533","journal-title":"Proteomics"},{"issue":"21","key":"778_CR19","first-page":"6141","volume":"62","author":"V Grunwald","year":"2002","unstructured":"Grunwald V, DeGraffenried L, Russel D, Friedrichs WE, Ray RB, Hidalgo M (2002) Inhibitors of mTOR reverse doxorubicin resistance conferred by PTEN status in prostate cancer cells. Cancer Res 62(21):6141\u20136145","journal-title":"Cancer Res"},{"issue":"20","key":"778_CR20","doi-asserted-by":"publisher","first-page":"6563","DOI":"10.1158\/1078-0432.CCR-11-1244","volume":"17","author":"TL Lotan","year":"2011","unstructured":"Lotan TL, Gurel B, Sutcliffe S, Esopi D, Liu W, Xu J, Hicks JL, Park BH, Humphreys E, Partin AW, Han M, Netto GJ, Isaacs WB, de Marzo AM (2011) PTEN protein loss by immunostaining: analytic validation and prognostic indicator for a high risk surgical cohort of prostate cancer patients. Clin Cancer Res 17(20):6563\u20136573","journal-title":"Clin Cancer Res"},{"issue":"6","key":"778_CR21","doi-asserted-by":"publisher","first-page":"792","DOI":"10.1016\/j.ccr.2011.05.006","volume":"19","author":"DJ Mulholland","year":"2011","unstructured":"Mulholland DJ, Tran LM, Li Y, Cai H, Morim A, Wang S, Plaisier S, Garraway IP, Huang J, Graeber TG, Wu H (2011) Cell autonomous role of PTEN in regulating castration-resistant prostate cancer growth. Cancer Cell 19(6):792\u2013804","journal-title":"Cancer Cell"},{"issue":"22","key":"778_CR22","doi-asserted-by":"publisher","first-page":"2271","DOI":"10.1056\/NEJMoa066838","volume":"356","author":"G Hudes","year":"2007","unstructured":"Hudes G, Carducci M, Tomczak P, Dutcher J, Figlin R, Kapoor A, Staroslawska E, Sosman J, McDermott D, Bodrogi I, Kovacevic Z, Lesovoy V, Schmidt-Wolf IGH, Barbarash O, Gokmen E, O'Toole T, Lustgarten S, Moore L, Motzer RJ (2007) Temsirolimus, interferon alfa, or both for advanced renal-cell carcinoma. N Engl J Med 356(22):2271\u20132281","journal-title":"N Engl J Med"},{"key":"778_CR23","doi-asserted-by":"publisher","first-page":"449","DOI":"10.1016\/S0140-6736(08)61039-9","volume":"372","author":"RJ Motzer","year":"2008","unstructured":"Motzer RJ (2008) Efficacy of everolimus in advanced renal cell carcinoma: a double-blind, randomised, placebo-controlled phase III trial. Lancet 372:449\u2013456","journal-title":"Lancet"},{"issue":"9808","key":"778_CR24","doi-asserted-by":"publisher","first-page":"2005","DOI":"10.1016\/S0140-6736(11)61742-X","volume":"378","author":"ME Pavel","year":"2011","unstructured":"Pavel ME, Hainsworth JD, Baudin E, Peeters M, Horsch D, Winkler RE et al (2011) Everolimus plus octreotide long-acting repeatable for the treatment of advanced neuroendocrine tumours associated with carcinoid syndrome (RADIANT-2): a randomised, placebo-controlled, phase 3 study. Lancet 378(9808):2005\u20132012","journal-title":"Lancet"},{"issue":"23","key":"778_CR25","doi-asserted-by":"publisher","first-page":"5314","DOI":"10.1200\/JCO.2005.66.130","volume":"23","author":"S Chan","year":"2005","unstructured":"Chan S, Scheulen ME, Johnston S, Mross K, Cardoso F, Dittrich C, Eiermann W, Hess D, Morant R, Semiglazov V, Borner M, Salzberg M, Ostapenko V, Illiger HJ, Behringer D, Bardy-Bouxin N, Boni J, Kong S, Cincotta M, Moore L (2005) Phase II study of temsirolimus (CCI-779), a novel inhibitor of mTOR, in heavily pretreated patients with locally advanced or metastatic breast cancer. J Clin Oncol 23(23):5314\u20135322","journal-title":"J Clin Oncol"},{"issue":"8","key":"778_CR26","doi-asserted-by":"publisher","first-page":"861","DOI":"10.1002\/pros.20752","volume":"68","author":"TM Morgan","year":"2008","unstructured":"Morgan TM, Pitts TE, Gross TS, Poliachik SL, Vessella RL, Corey E (2008) RAD001 (Everolimus) inhibits growth of prostate cancer in the bone and the inhibitory effects are increased by combination with docetaxel and zoledronic acid. Prostate 68(8):861\u2013871","journal-title":"Prostate"},{"issue":"1","key":"778_CR27","doi-asserted-by":"publisher","first-page":"150","DOI":"10.1016\/j.eururo.2013.03.040","volume":"64","author":"AJ Templeton","year":"2013","unstructured":"Templeton AJ, Dutoit V, Cathomas R, Rothermundt C, Bartschi D, Droge C et al (2013) Phase 2 trial of single-agent everolimus in chemotherapy-naive patients with castration-resistant prostate cancer (SAKK 08\/08). Eur Urol 64(1):150\u2013158","journal-title":"Eur Urol"},{"issue":"11","key":"778_CR28","doi-asserted-by":"publisher","first-page":"3057","DOI":"10.1158\/1078-0432.CCR-10-0124","volume":"16","author":"AJ Armstrong","year":"2010","unstructured":"Armstrong AJ, Netto GJ, Rudek MA, Halabi S, Wood DP, Creel PA, Mundy K, Davis SL, Wang T, Albadine R, Schultz L, Partin AW, Jimeno A, Fedor H, Febbo PG, George DJ, Gurganus R, de Marzo AM, Carducci MA (2010) A pharmacodynamic study of rapamycin in men with intermediate- to high-risk localized prostate cancer. Clin Cancer Res 16(11):3057\u20133066","journal-title":"Clin Cancer Res"},{"issue":"11","key":"778_CR29","doi-asserted-by":"publisher","first-page":"1729","DOI":"10.1111\/j.1464-410X.2012.11456.x","volume":"110","author":"M Nakabayashi","year":"2012","unstructured":"Nakabayashi M, Werner L, Courtney KD, Buckle G, Oh WK, Bubley GJ, Hayes JH, Weckstein D, Elfiky A, Sims DM, Kantoff PW, Taplin ME (2012) Phase II trial of RAD001 and bicalutamide for castration-resistant prostate cancer. BJU Int 110(11):1729\u20131735","journal-title":"BJU Int"},{"issue":"5","key":"778_CR30","doi-asserted-by":"publisher","first-page":"1499","DOI":"10.1200\/JCO.1999.17.5.1499","volume":"17","author":"MW Kattan","year":"1999","unstructured":"Kattan MW, Wheeler TM, Scardino PT (1999) Postoperative nomogram for disease recurrence after radical prostatectomy for prostate cancer. J Clin Oncol 17(5):1499\u20131507","journal-title":"J Clin Oncol"},{"key":"778_CR31","unstructured":"Edge S BD, Compton CC, Fritz AG, Greene FL, Trotti A. AJCC (2010) Cancer Staging Manual. Springer, 649 p"},{"issue":"5","key":"778_CR32","doi-asserted-by":"publisher","first-page":"1811","DOI":"10.1016\/j.juro.2008.01.026","volume":"179","author":"K Touijer","year":"2008","unstructured":"Touijer K, Eastham JA, Secin FP, Romero Otero J, Serio A, Stasi J, Sanchez-Salas R, Vickers A, Reuter VE, Scardino PT, Guillonneau B (2008) Comprehensive prospective comparative analysis of outcomes between open and laparoscopic radical prostatectomy conducted in 2003 to 2005. J Urol 179(5):1811\u20131817 discussion 7","journal-title":"J Urol"},{"issue":"16","key":"778_CR33","doi-asserted-by":"publisher","first-page":"7052","DOI":"10.1158\/0008-5472.CAN-05-0917","volume":"65","author":"SY Sun","year":"2005","unstructured":"Sun SY, Rosenberg LM, Wang X, Zhou Z, Yue P, Fu H, Khuri FR (2005) Activation of Akt and eIF4E survival pathways by rapamycin-mediated mammalian target of rapamycin inhibition. Cancer Res 65(16):7052\u20137058","journal-title":"Cancer Res"},{"issue":"4","key":"778_CR34","first-page":"714","volume":"6","author":"N Dey","year":"2016","unstructured":"Dey N, Sun Y, Carlson JH, Wu H, Lin X, Leyland-Jones B et al (2016) Anti-tumor efficacy of BEZ235 is complemented by its anti-angiogenic effects via downregulation of PI3K-mTOR-HIF1alpha signaling in HER2-defined breast cancers. Am J Cancer Res 6(4):714\u2013746","journal-title":"Am J Cancer Res"},{"issue":"3","key":"778_CR35","doi-asserted-by":"publisher","first-page":"1500","DOI":"10.1158\/0008-5472.CAN-05-2925","volume":"66","author":"KE O'Reilly","year":"2006","unstructured":"O'Reilly KE, Rojo F, She QB, Solit D, Mills GB, Smith D, Lane H, Hofmann F, Hicklin DJ, Ludwig DL, Baselga J, Rosen N (2006) mTOR inhibition induces upstream receptor tyrosine kinase signaling and activates Akt. Cancer Res 66(3):1500\u20131508","journal-title":"Cancer Res"},{"issue":"5","key":"778_CR36","doi-asserted-by":"publisher","first-page":"403","DOI":"10.1016\/j.ctrv.2012.12.002","volume":"39","author":"P De","year":"2013","unstructured":"De P, Miskimins K, Dey N, Leyland-Jones B (2013) Promise of rapalogues versus mTOR kinase inhibitors in subset specific breast cancer: old targets new hope. Cancer Treat Rev 39(5):403\u2013412","journal-title":"Cancer Treat Rev"},{"issue":"4","key":"778_CR37","doi-asserted-by":"publisher","first-page":"222","DOI":"10.1038\/nrurol.2018.9","volume":"15","author":"T Jamaspishvili","year":"2018","unstructured":"Jamaspishvili T, Berman DM, Ross AE, Scher HI, De Marzo AM, Squire JA et al (2018) Clinical implications of PTEN loss in prostate cancer. Nat Rev Urol 15(4):222\u2013234","journal-title":"Nat Rev Urol"},{"issue":"33","key":"778_CR38","doi-asserted-by":"publisher","first-page":"55582","DOI":"10.18632\/oncotarget.16029","volume":"8","author":"F Weeber","year":"2017","unstructured":"Weeber F, Cirkel GA, Hoogstraat M, Bins S, Gadellaa-van Hooijdonk CGM, Ooft S et al (2017) Predicting clinical benefit from everolimus in patients with advanced solid tumors, the CPCT-03 study. Oncotarget 8(33):55582\u201355592","journal-title":"Oncotarget"},{"issue":"suppl_6","key":"778_CR39","first-page":"718O","volume":"27","author":"JS de Bono","year":"2016","unstructured":"de Bono JS, De Giorgi U, Massard C, Bracarda S, Nava Rodrigues D, Kocak I et al (2016) PTEN loss as a predictive biomarker for the Akt inhibitor ipatasertib combined with abiraterone acetate in patients with metastatic castration-resistant prostate cancer (mCRPC). Ann Oncol 27(suppl_6):718O\u2013718O","journal-title":"Ann Oncol"}],"container-title":["Investigational New Drugs"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10637-019-00778-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s10637-019-00778-4\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10637-019-00778-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,3,11]],"date-time":"2023-03-11T18:32:24Z","timestamp":1678559544000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s10637-019-00778-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,4,30]]},"references-count":39,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2019,6,15]]}},"alternative-id":["778"],"URL":"https:\/\/doi.org\/10.1007\/s10637-019-00778-4","relation":{},"ISSN":["0167-6997","1573-0646"],"issn-type":[{"value":"0167-6997","type":"print"},{"value":"1573-0646","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,4,30]]},"assertion":[{"value":"11 March 2019","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"3 April 2019","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"30 April 2019","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}},{"value":"All authors declare that they have no specific conflicts of interest related to this manuscript. Jorge A. Garcia received Research Funding - paid to institution: Novartis and GSK.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"All procedures performed in this study involving human participants were approved by the Cleveland Clinic Institutional Review Board. All procedures were in accordance with the ethical standards of the institutional research committee and with the 1964 Helsinki declaration and its later amendments or comparable ethical standards.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}},{"value":"Informed consent was obtained from all individual participants included in the study.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Informed consent"}}]}}